Drugmakers Think Blockchains Could Improve Clinical Trials
Three big pharmaceutical firms—Pfizer, Amgen, and Sanofi—are working together to use blockchains to speed up clinical tests of new drugs, according to CoinDesk.
The problem: Patient data that’s crucial to locating individuals for clinical trials is usually scattered across multiple proprietary systems that are often incompatible with each other. That can make it hard to recruit for trials.
How blockchains could help: A distributed ledger could allow individual patients to store data anonymously and make it visible to trial recruiters, who could then reach out to individuals who meet the eligibility criteria for a given trial. It could also streamline communication between doctors and patients during the trial.
It’s still early: Technologists are still mostly experimenting with blockchain-based medical records systems, and big technical challenges remain. The health-care industry is also heavily regulated and tends to be risk averse, which could impede adoption.
Keep Reading
Most Popular
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
ChatGPT is going to change education, not destroy it
The narrative around cheating students doesn’t tell the whole story. Meet the teachers who think generative AI could actually make learning better.
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.